Prescribing direct-acting antivirals for hepatitis C treatment: a scoping review of factors that influence primary care providers
Authors:
Open Access
- 13 May 2025
- journal article
- review article
- Published by Springer Nature in BMC Primary Care
- Vol. 26 (1) , 1-11
Abstract
Hepatitis C is a significant public health challenge in Australia, particularly in diagnosis, treatment access, and ongoing care among people who inject drugs. Despite the availability of highly effective direct-acting antivirals and government subsidisation, treatment uptake has declined among this population in recent years, beyond what would be expected from the initial treatment of easier-to-reach patients. This rapid scoping review aimed to identify barriers and enablers affecting primary care providers in prescribing direct-acting antivirals for hepatitis C treatment. Studies were included if they: were published after 2014, focused on DAA treatment, included primary care provider perspectives, contained primary data, identified barriers/enablers to treatment, and were conducted in high-income countries. Two databases (Web of Science and Google Scholar) were searched for peer-reviewed articles. Primary care stakeholders were consulted through an online survey (n = 10) and telephone interviews (n = 7) to contextualise and validate findings. Data were charted using a standardised form capturing author, year, location, aim, participants, study details, and main findings. Analysis used a deductive approach to identify key themes. Twenty-three articles, mostly quantitative studies, were included in the review. The analysis identified four key domains influencing direct-acting antiviral prescription: provider characteristics, healthcare systems and service delivery, models of care, and societal and structural issues. This review provides insights into contemporary challenges in hepatitis C care delivery models and highlights critical structural, sociocultural, and interpersonal factors affecting testing and treatment, particularly for people who inject drugs. These findings have implications for improving direct-acting antiviral prescription rates in primary care settings.Keywords
Funding Information
- HepatitisWA
This publication has 72 references indexed in Scilit:
- The State of Hepatitis C Elimination from the Front Lines: A Qualitative Study of Provider-Perceived Gaps to Treatment InitiationJournal of General Internal Medicine, 2024
- Global Hepatitis C Virus Elimination — Where Are We?Current Hepatology Reports, 2024
- The changing characteristics of patients with chronic hepatitis C prescribed direct acting antiviral medicines in general practice since listing of the medicines on the Australian Pharmaceutical Benefits SchemeJGH Open, 2021
- Knowledge, Attitudes, and Behaviors Related to Hepatitis C Screening and Treatment among Health Care Providers in Washington, DCJournal of Community Health, 2020
- A cost-effectiveness analysis of primary versus hospital-based specialist care for direct acting antiviral hepatitis C treatmentInternational Journal of Drug Policy, 2020
- Barriers and facilitators to engaging in hepatitis C management and DAA therapy among general practitioners and drug and alcohol specialists—The practitioner experienceDrug and Alcohol Dependence, 2020
- Perceptions and self-reported competency related to testing, management and treatment of hepatitis C virus infection among physicians prescribing opioid agonist treatment: The C-SCOPE studyInternational Journal of Drug Policy, 2019
- Identifying barriers to treatment of HCV in the primary care settingHepatology International, 2018
- ‘Hep C’s like the common cold’: understanding barriers along the HCV care continuum among young people who inject drugsDrug and Alcohol Dependence, 2018
- Primary Care Physician Perspectives on Hepatitis C Management in the Era of Direct-Acting Antiviral TherapyDigestive Diseases and Sciences, 2016